Activity Survey 2022: CAR-T activity continues to grow; transplant activity has slowed

Main trends observed in the numbers of HCT reported in 2022.
- Transplant activity decreases again after the increase observed in 2021 post pandemic.
- Numbers declined across many indications and donor type suggesting a general rather than a disease specific cause.
- Allogeneic HCT: -4.0% (+5.4% in 2021), autologous HCT: -1.7% (+3.9% in 2021).
- Donor choice showed continued trend moving away from HLA-identical family donors and possibly haplo-identical donors, while the use of unrelated donors seems to have stabilized.
- Use of sibling donors decreased by -7.7%, haploidentical donors by -6.3% and unrelated donors by -0.9%.
- Overall cord blood HCT decreased by -16% (N= 273 in 2022, 325 in 2021).
- Decrease in allogeneic and autologous HCT activity in lymphoid malignancies may be attributed to new therapeutic options available, i.e., small molecules, monoclonal antibodies, bispecific antibodies and most notably, CAR-T cells.
- Overall, after many years of continuous growth application for HCT seems to have slowed down.

Main Indication 1st HCT
- Myeloid malignancies: 10 433
- Lymphoid malignancies: 4 674
- Solid tumours: 28
- Bone marrow failure: 1 065
- Other non-malignant disorders: 1 507
- Other: 155

Myeloid malignancies
- AML 1st, CR: 4 181
- not 1st, CR: 1 640
- AML: therapy or MDS related: 1 140
- CML 1st, cP: 164
- not 1st, cP: 167
- MDS or MDS/MPN, MPN: 3 141

Lymphoid malignancies
- ALL 1st, CR: 1 884
- not 1st, CR: 1 167
- CLL: 157
- Plasma cell disorders: 187
- Hodgkin lymphoma: 348
- Non-Hodgkin lymphoma: 931

Solid tumours
- Neuroblastoma: 26
- Soft tissue sarcoma/Ewing: 1
- Germ cell tumour: 1
- Other solid tumour: 1

Non malignant disorders
- Bone marrow failure - SAA: 787
- Bone marrow failure - other: 278
- Thalassemia: 356
- Sickle cell disease: 333
- Primary immune deficiency: 636
- Inherited disorder of metabolism: 153
- Auto immune disease: 29
- Others: 155

Allogeneic HCT: N= 5 452: 4 130 allogeneic (+2.5%), 1 322 auto (-6.2%).
- Allogeneic cell source: BM: 2 083 (34% unrelated), PBSC: 1 891 (48% unrelated), CB: 156 (88% unrelated).
- Un-manipulated DLI: N= 2 854; graft enhancement/failure: 804; residual disease: 393; relapse: 1 294; per protocol: 363.
- Non HCT cellular therapies using manipulated or selected cells:

Epub: JR, Passweg, H. Baldomero et al, Bone Marrow Transplantation, February 2024.
Contact: helen.baldomero@usb.ch